Cardiovascular safety of empagliflozin in patients with Type 2 diabetes: a metaanalysis of placebo-controlled trials

被引：0
|
作者：
Salsali, A. [1 ]
Kim, G. [2 ]
Woerle, H. J. [2 ]
Broedl, U. C. [2 ]
Hantel, S. [3 ]
机构：
[1] Boehringer Ingelheim Pharmaceut Inc, Diabet Clin Res, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Med IA Metab, Ingelheim, Germany
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biostat & Data Sci, Biberach, Germany
来源：
DIABETIC MEDICINE | 2017年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A74
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [41] Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
    Lehrke, Michael
    Marx, Nikolaus
    Patel, Sanjay
    Seck, Thomas
    Crowe, Susanne
    Cheng, Karen
    von Eynatten, Maximilian
    Johansen, Odd Erik
    CLINICAL THERAPEUTICS, 2014, 36 (08) : 1130 - 1146
  • [42] Empagliflozin and cardiovascular endpoints in patients with type 2 diabetes mellitus
    Guthoff M.
    Der Nephrologe, 2016, 11 (3): : 217 - 218
  • [43] Introduction to commentaries on the use of placebo-controlled trials of flew therapies in the treatment of type 2 diabetes
    Clark, CM
    DIABETES CARE, 2001, 24 (04) : 768 - 768
  • [44] Meta-analysis of double-blind, placebo-controlled trials investigating the efficacy and safety of miglitol in combination with metformin in patients with type 2 diabetes
    Diani, AR
    Cromie, MA
    Zhang, S
    Schmid, C
    Gordon, M
    Ross, S
    Chadbourne, E
    DIABETES, 2000, 49 : A356 - A357
  • [45] Blood pressure reduction with empagliflozin in Japanese patients with type 2 diabetes and cardiovascular diseases: a post-hoc sub-analysis of the placebo-controlled randomized EMBLEM trial
    Tanaka, Atsushi
    Shimabukuro, Michio
    Teragawa, Hiroki
    Yoshida, Hisako
    Okada, Yosuke
    Takamura, Toshinari
    Taguchi, Isao
    Toyoda, Shigeru
    Tomiyama, Hirofumi
    Ueda, Shinichiro
    Higashi, Yukihito
    Node, Koichi
    HYPERTENSION RESEARCH, 2024, 47 (09) : 2295 - 2302
  • [46] Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials
    Toto, Robert D.
    Goldenberg, Ronald
    Chertow, Glenn M.
    Cain, Valerie
    Stefansson, Bergur, V
    Sjostrom, C. David
    Sartipy, Peter
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2019, 33 (10)
  • [47] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Fitchett, David
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    van de Borne, Philippe
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    George, Jyothis T.
    Zinman, Bernard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) : 364 - 367
  • [48] A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
    Gantz, Ira
    Chen, Menghui
    Suryawanshi, Shailaja
    Ntabadde, Catherine
    Shah, Sukrut
    O'Neill, Edward A.
    Engel, Samuel S.
    Kaufman, Keith D.
    Lai, Eseng
    CARDIOVASCULAR DIABETOLOGY, 2017, 16
  • [49] A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
    Ira Gantz
    Menghui Chen
    Shailaja Suryawanshi
    Catherine Ntabadde
    Sukrut Shah
    Edward A. O’Neill
    Samuel S. Engel
    Keith D. Kaufman
    Eseng Lai
    Cardiovascular Diabetology, 16
  • [50] A METAANALYSIS OF DOUBLE-BLIND PLACEBO-CONTROLLED TRIALS OF CLONIDINE FOR SMOKING CESSATION
    COVEY, LS
    GLASSMAN, AH
    BRITISH JOURNAL OF ADDICTION, 1991, 86 (08): : 991 - 998
12345